Search Results - Ericka M Ebot

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy by Ericka M. Ebot, Daniel L. Duncan, Khaled Tolba, David Fabrizio, Garrett M. Frampton, Leah A. Comment, Lee A. Albacker

    Published in npj Precision Oncology (2022-06-01)
    Get full text
    Article


  2. 2

    Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivol... by Jie He, David Fabrizio, Jonathan Baden, Parul Doshi, James Pratt, Lee A Albacker, Geoffrey R Oxnard, Gina Fusaro, Natallia Kalinava, Dean C Pavlick, Ericka M Ebot, Hanna Tukachinsky, George Green

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Get full text
    Article


  3. 3

    Transcriptional landscape of PTEN loss in primary prostate cancer by Eddie Luidy Imada, Diego Fernando Sanchez, Wikum Dinalankara, Thiago Vidotto, Ericka M. Ebot, Svitlana Tyekucheva, Gloria Regina Franco, Lorelei Ann Mucci, Massimo Loda, Edward Matthew Schaeffer, Tamara Lotan, Luigi Marchionni

    Published in BMC Cancer (2021-07-01)
    Get full text
    Article


  4. 4

    A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study by Barbra A. Dickerman, Ericka M. Ebot, Brian C. Healy, Kathryn M. Wilson, A. Heather Eliassen, Alberto Ascherio, Claire H. Pernar, Oana A. Zeleznik, Matthew G. Vander Heiden, Clary B. Clish, Edward Giovannucci, Lorelei A. Mucci

    Published in Metabolites (2020-03-01)
    Get full text
    Article


Search Tools: